Crossmark

89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer

Crossref DOI link: https://doi.org/10.1038/s41591-018-0255-8

Published Online: 2018-11-26

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Bensch, Frederike

van der Veen, Elly L.

Lub-de Hooge, Marjolijn N.

Jorritsma-Smit, Annelies

Boellaard, Ronald

Kok, Iris C.

Oosting, Sjoukje F.

Schröder, Carolina P.

Hiltermann, T. Jeroen N.

van der Wekken, Anthonie J.

Groen, Harry J. M.

Kwee, Thomas C.

Elias, Sjoerd G.

Gietema, Jourik A.

Bohorquez, Sandra Sanabria

de Crespigny, Alex

Williams, Simon-Peter

Mancao, Christoph

Brouwers, Adrienne H.

Fine, Bernard M. https://orcid.org/0000-0002-5483-476X
de Vries, Elisabeth G. E. https://orcid.org/0000-0002-8949-7425
License Information

Text and Data Mining valid from 2018-11-26
More Information

Article History

Received: 9 March 2018

Accepted: 10 September 2018

First Online: 26 November 2018

Competing interests

: The authors declare the following as competing interests: H.J.M.G. received research support from Hoffmann–La Roche (payment to the institution) and has an advisory role for Roche Netherlands; B.M.F., C.M., S.S.B., A.d.C., and S.-P.W. are employed by Hoffman–La Roche/Genentech and own stock in Hoffman–La Roche/Genentech; E.G.E.d.V. received research support from Hoffman–La Roche/Genentech (payment to the institution) and is a member of the ESMO Magnitude of Clinical Benefit Scale.